chronic conditions: congestive heart failure, ischemic heart disease, stroke, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, Alzheimer's, and colon or lung cancer.
In 2 clinical trials of 1,108 participants, those who took 2 pills every 12 hours demonstrated improved lung function compared to placebo. ... Gefitinib (Iressa) for first-line treatment of metastatic non-small-cell lung cancer in which tumors harbor
Treatment of lung cancer involves choosing among a different set of drugs than would be considered for brain or kidney cancer. ... about viral and other, unusual infections in patients are immunocompromised after kidney, heart or lung transplants.
And she had a stricken look on her face. Of course, I was sure that I had lung cancer. ... Dr. Arnold said she remembers thinking at the time, “‘All right, I do have lung cancer, that's what's going on.’ But the biopsy was negative for malignancy,
I have a cough" may be bronchitis (wink-wink), it may be lung cancer, or it may be the blood pressure pill someone was given a month ago.
Unsurprisingly, one of the research groups concluded that the effect on lung cancer risk was mediated indirectly through changes in smoking behavior. ... Intriguingly, the authors of the other two studies concluded that the risk of lung cancer conferred
American Society of Clinical Oncology issued a provisional clinical opinion that patients with metastatic non-small-cell lung cancer should be offered palliative care and standard oncologic care when they are ... diagnosed. The opinion reads, "Although
Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. ... 2010;363:733-42. [PMID: 20818875] doi:10.1056/NEJMoa1000678) that demonstrated [that] for people with metastatic lung cancer, the introduction of palliative
Cable described a 59-year-old man in remission from lung cancer after having been treated with surgery and adjuvant chemotherapy 1 year before. ... Cable said. SVC is often seen in small-cell lung cancer and lymphoma (Hodgkin or primary mediastinal
An expanded approval of ramucirumab (Cyramza) to treat metastatic non-small cell lung cancer (NSCLC). ... The drug was approved last year to treat advanced stomach cancer or gastroesophageal junction adenocarcinoma.